vTv Therapeutics Wins FDA Orphan Drug Status for Sickle Cell Condition
The FDA granted orphan drug designation to vTv Therapeutics for HPPD in sickle cell disease, supporting partnering efforts alongside its T1D program.
vTv Therapeutics has secured FDA Orphan Drug Designation for its treatment targeting hereditary persistence of fetal hemoglobin, or HPPD, in patients with sickle cell disease, the company announced. The designation is a regulatory milestone that typically confers development incentives including tax credits, reduced filing fees, and seven years of market exclusivity upon approval.
The company said the orphan designation is expected to bolster ongoing partnering discussions around the HPPD program. Orphan status signals to potential partners that the FDA has recognized the unmet medical need for the condition, which affects a relatively small patient population and historically attracts limited commercial investment without such incentives.
Read more Hilco Real Estate Seeks Buyers for Detroit Rail-Served Industrial Sites →
Despite the new designation, vTv Therapeutics emphasized that its primary strategic focus remains cadisegliatin, a late-stage drug candidate for type 1 diabetes. The company positioned the HPPD milestone as complementary to, rather than a diversion from, its flagship diabetes program, suggesting it views partnership or licensing as the likely commercial path for the sickle cell asset.
Sickle cell disease is a serious inherited blood disorder that affects millions of people worldwide, with patients in the United States disproportionately drawn from minority communities. Regulatory designations like the one granted to vTv can accelerate development timelines and reduce financial risk for smaller biotechnology firms pursuing treatments for such conditions.
Continue reading at GlobeNewswire - Industry News on Financial Services.
